Aquestive Therapeutics Profit Margin

Aquestive Therapeutics (AQST) currently reports a profit margin of -137.08% as of March 2026. That compares with -100.02% in the prior-year period — down 37.1% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Aquestive Therapeutics's profit margin history and peer comparisons.

Aquestive Therapeutics's profit margin decreased from -100.02% to -137.08% — a 37.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aquestive Therapeutics's profit margin of -137.08% is lower than the Healthcare sector average of 14.34%. That is roughly 1055.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Aquestive Therapeutics's current -137.08% should be judged against Healthcare norms (sector average: 14.34%) and against AQST's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -137.08%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Aquestive Therapeutics, and consider following AQST for alerts when major investors trade the stock.